Perspective Therapeutics filings document a clinical-stage radiopharmaceutical oncology business built around Lead-212 targeted therapy, imaging diagnostics, and regional manufacturing capabilities. Form 8-K reports include clinical-program exhibits, corporate presentations, preliminary financial information, and annual results for its VMT-α-NET, VMT01, and PSV359 programs.
The company’s SEC record also covers capital-structure matters, including common stock and pre-funded warrant offerings under a shelf registration statement, as well as material agreements, proxy disclosures on board matters, executive compensation, equity awards, shareholder voting items, governance, and other public-company reporting obligations.
Perspective Therapeutics, Inc. (CATX) reported updated interim results from its Phase 1/2a study of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors. Objective response rates were 33% (15 of 46 patients) in Cohort 2 at 5.0 mCi and 50% (10 of 20) in Cohort 3 at 6.0 mCi. The rates include confirmed and unconfirmed responses; the Cohort 3 figure includes two additional unconfirmed partial responses reported as of September 10, 2026. Disease control rates were 89% and 95%, respectively. Progression-free survival across all three cohorts was 86% at six months, 74% at 12 months and 72% at 18 months.
No dose-limiting toxicities, Grade 4 or 5 treatment-emergent adverse events, or adverse event-related treatment discontinuations were reported. Grade 3 treatment-emergent adverse events occurred in 20 of 68 patients (29%), including Grade 3 renal events in two patients (2.9%). Perspective aims to complete Phase 3 site start-up preparations around year-end 2026, with site activation following an End-of-Phase 2 meeting with the FDA and Phase 3 initiation expected in 2027.
Perspective Therapeutics, Inc. (CATX) announced that the FDA granted Fast Track Designation for development of PSV359 in adults with locally advanced unresectable and/or metastatic FAP-positive solitary fibrous tumors. The company describes PSV359 as an investigational FAP-targeted alpha-particle therapy in an ongoing Phase 1/2a study of patients with advanced FAP-positive solid tumors.
The study is multicenter, open-label, and includes dose-finding and dose-expansion phases. Dose-finding assesses safety and tolerability across various doses to inform selection of a recommended Phase 2 dose; antitumor activity may be evaluated as an additional primary outcome in the expansion phase. The release says patients with advanced disease have limited treatment options.
Perspective Therapeutics, Inc. updated its corporate presentation on October 1, 2026, outlining its radiopharmaceutical oncology pipeline. The presentation describes three independent clinical-stage programs—VMT-α-NET, VMT01 and PSV359—each aimed at a distinct target, with data in 2026 and ongoing Phase 1/2a studies. It states that VMT-α-NET, VMT01, PSV359 and PSV594 address a combined $45 billion-plus solid-tumor market. The presentation reports preliminary anti-tumor activity for VMT01 at a 3.0 mCi dose and says VMT-α-NET’s profile supports a potential registration study at its current dose level.
Perspective Therapeutics, Inc. (CATX) is the issuer whose common stock Lantheus Alpha Therapy, LLC reported selling on the open market during September 2026. The reported sales were 167,149 shares at an average sales price of $3.1472 per share; 92,442 at $3.133; 65,500 at $3.0098; 13,450 at $2.9531; 750,000 at $2.85; 215,974 at $2.9645; and 1,396,987 at $2.8976, respectively. As of September 22, 2026, Lantheus Alpha directly held 8,739,011 shares, reported as 7.7% of the common stock. Lantheus Medical Imaging, Inc. and Lantheus Holdings, Inc. may each be deemed to share voting and dispositive power over those shares. The reported percentage is based on 114,151,663 shares outstanding as of August 5, 2026.
Perspective Therapeutics, Inc. (CATX) reported that it entered into a clinical trial collaboration and supply agreement with Merck to evaluate Perspective’s targeted alpha-particle therapy [212Pb]PSV359 in combination with Merck’s Keytruda (pembrolizumab) in FAP-α–positive solid tumors.
The combination will be studied under an amendment to Perspective’s ongoing Phase 1/2a trial (NCT06710756) in certain non-small cell lung and colorectal cancers that express FAP-α. Perspective is sponsoring the study, and Merck will provide pembrolizumab at no cost. Enrollment has been completed in the first three monotherapy dose cohorts.
Perspective Therapeutics, Inc. (CATX) reported that it updated its corporate presentation, which has been furnished as an exhibit. The presentation outlines a strategy focused on next‑generation radiopharmaceutical therapy in targeted oncology built around lead‑212 (²¹²Pb) payloads.
The company highlights three independent clinical‑stage programs targeting distinct receptors or antigens: VMT-α-NET for SSTR2+ neuroendocrine tumors, VMT01 for melanoma via MC1R, and PSV359 for FAP-ɑ–expressing solid tumors, along with a CCK2R program. The materials describe an estimated $45 billion+ combined solid tumor addressable market for programs VMT-α-NET, VMT01, PSV359, and PSV594, ongoing Phase 1/2a trials, clinical data expected in 2026 including ASCO 2026 analyses, and an integrated platform covering isotope production, regional manufacturing, and intellectual property across the radiopharmaceutical value chain.
Perspective Therapeutics, Inc. (CATX) reported that Lantheus Alpha Therapy, LLC, a ten percent owner, sold shares of its common stock in open-market transactions on September 3 and September 4, 2026. The sales totaled 247,932 shares of common stock at weighted average prices around $3.11–$3.15 per share.
The shares are directly held by Lantheus Alpha Therapy, LLC, which is an indirect wholly owned subsidiary of Lantheus Holdings, Inc. Under SEC rules, Lantheus Holdings, Inc. may be deemed to have indirect beneficial ownership of these shares through Lantheus Alpha Therapy, LLC.
Perspective Therapeutics, Inc. (CATX) reported that significant stockholder Lantheus Alpha Therapy, LLC sold 42,129 shares of CATX common stock on September 2, 2026 in an open-market or private transaction at a weighted average price of $3.1147 per share, with individual trade prices ranging from $3.025 to $3.235. After this sale, Lantheus Alpha Therapy, LLC directly holds 11,521,296 CATX shares, and Lantheus Holdings, Inc., as its indirect parent, may be deemed to have indirect beneficial ownership of those shares under SEC rules.
Perspective Therapeutics, Inc. (CATX) disclosed that Lantheus Alpha Therapy, LLC, a ten percent owner and subsidiary of Lantheus Holdings, Inc., reported selling a total of 113,914 shares of CATX common stock in open-market or private transactions on August 31 and September 1, 2026. The August 31 sale covered 78,145 shares at a weighted average price of $3.143 per share, with individual trades between $3.095 and $3.165. The September 1 sale covered 35,769 shares at a weighted average price of $3.1193, with trades between $3.08 and $3.165. The share amounts reflect Perspective Therapeutics’ 1-for-10 reverse stock split effective June 14, 2024, and the filing notes that Lantheus Holdings may be deemed to have indirect beneficial ownership of the shares held directly by Lantheus Alpha Therapy.
Perspective Therapeutics, Inc. (CATX) discloses in this Schedule 13D/A (Amendment No. 2) that Lantheus Holdings, Inc., Lantheus Medical Imaging, Inc., and Lantheus Alpha Therapy, LLC collectively report beneficial ownership of 11,440,513 shares of CATX common stock, representing 10.0% of the class, based on 114,151,663 shares outstanding as of August 5, 2026. All shares are directly held by Lantheus Alpha, with all three Lantheus entities deemed to share voting and dispositive power.
The amendment is filed to reflect dilution of the reporting group’s beneficial ownership and to report dispositions of CATX shares on August 31, 2026, September 1, 2026, September 2, 2026 and September 3, 2026 at average prices just above $3.10 per share. It also notes a 1-for-10 reverse stock split of CATX common stock effective June 14, 2024 and confirms that the reported share figures are split-adjusted.